Special Notice · S-194657
TECHNOLOGY LICENSING OPPORTUNITY: NanoFET
NanoFiber Engineered Therapeutics Platform (NanoFET) from Los Alamos National Laboratory offers pharmaceutical and biodefense organizations a modular, adaptable scaffold for building next-generation immunotherapies. By merging self-assembling peptide nanofibers with interchangeable nanobody and peptide components, the platform enables rapid development of targeted treatments that bridge disease agents directly to the patient�s own immune cells. Infectious diseases and chronic conditions such as cancer continue to impose enormous public health and economic burdens worldwide. Conventional vaccines and biologics are typically designed against a single pathogen or target, leaving populations vulnerable when new or unknown threats emerge. For military personnel and first responders, the absence of broad-spectrum medical countermeasures means that exposure to an unidentified pathogen in the field can be met with little more than supportive care. In cancer immunotherapy, connecting tumor cel…
Excerpt as published. The complete description, attachments, and any amendments are on the official notice.
GrantSet indexes public records and is not the official application channel. Responses and applications go through SAM.gov only — the official notice there controls if anything shown here differs.